{"content":[{"text":"27 patients with relapsed and refractory AL amyloidosis who had previously not had an organ response to \n standard of care therapy. CAEL-101 has received Orphan Drug Designation from both the U.S. Food and Drug \n Administration and European Medicine Agency as a potential therapy for patients with AL amyloidosis.","bbox":{"left":0.081765,"top":0.054194,"width":0.83645,"height":0.053708}},{"text":"About AL Amyloidosis \n AL amyloidosis is a rare systemic disorder caused by an abnormality of plasma cells in the bone marrow. \n Misfolded immunoglobulin light chains produced by plasma cells aggregate and form fibrils that deposit in \n tissues and organs. This deposition can cause widespread and progressive organ damage and high mortality \n rates, with death most frequently occurring as a result of cardiac failure. Current standard of care includes \n plasma cell directed chemotherapy and autologous stem cell transplant, but these therapies do not address the \n organ dysfunction caused by amyloid deposition, and up to 80 percent of patients are ineligible for transplant.","bbox":{"left":0.081765,"top":0.129826,"width":0.8365960000000001,"height":0.12928800000000001}},{"text":"AL amyloidosis is a rare disease but is the most common form of systemic amyloidosis. There are approximately \n 22,000 patients across the United States, France, Germany, Italy, Spain and the United Kingdom. AL amyloidosis \n has a one-year mortality rate of 47 percent, 76 percent of which is caused by cardiac amyloidosis.","bbox":{"left":0.081765,"top":0.281075,"width":0.836896,"height":0.05353199999999997}},{"text":"About Caelum Biosciences \n Caelum Biosciences, Inc. (“Caelum”) is a clinical-stage biotechnology company developing treatments for rare \n and life-threatening diseases. Caelum’s lead asset, CAEL-101, is a novel antibody for the treatment of patients \n with amyloid light chain (“AL”) amyloidosis. In 2019, Caelum entered a collaboration agreement with Alexion \n under which Alexion acquired a minority equity interest in Caelum and an exclusive option to acquire the \n remaining equity in the company. Caelum was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more \n information, visit www.caelumbio.com.","bbox":{"left":0.081765,"top":0.356682,"width":0.8366140000000001,"height":0.129162}},{"text":"About Alexion \n Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare \n diseases and devastating conditions through the discovery, development and commercialization of life-changing \n medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two \n approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical \n hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti- \n acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica \n spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients \n with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase \n deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the \n company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, \n an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral \n Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second \n oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules \n and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, \n metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, \n Alexion has offices around the globe and serves patients in more than 50 countries. This press release and \n further information about Alexion can be found at: www.alexion.com. \n [ALXN-P]","bbox":{"left":0.081765,"top":0.507919,"width":0.837026,"height":0.35586700000000004}},{"text":"Forward-Looking Statement \n This press release contains forward-looking statements that involve risks and uncertainties relating to future \n events and the future performance of Alexion and its products, including statements related to: the anticipated","bbox":{"left":0.081765,"top":0.885861,"width":0.836489,"height":0.053530999999999995}},{"text":"2","bbox":{"left":0.494788,"top":0.948437,"width":0.010579000000000005,"height":0.01580400000000004}}],"images_bbox":[],"images_bbox_not_text_overlap":[]}